Suppr超能文献

初发血液透析患者矿物质和骨代谢紊乱的持续控制

Consistent control of mineral and bone disorder in incident hemodialysis patients.

作者信息

Danese Mark D, Belozeroff Vasily, Smirnakis Karen, Rothman Kenneth J

机构信息

Outcomes Insights, Inc., Newbury Park, California, USA.

出版信息

Clin J Am Soc Nephrol. 2008 Sep;3(5):1423-9. doi: 10.2215/CJN.01060308. Epub 2008 Jul 2.

Abstract

BACKGROUND AND OBJECTIVES

In 2003, the National Kidney Foundation introduced guidelines for the control of parathyroid hormone, calcium, and phosphorus in hemodialysis patients.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cohort study was conducted of 22,937 incident hemodialysis patients who were identified from a large national provider between July 1, 2000, and June 30, 2002, and followed through June 30, 2004. Consistent achievement was determined (1) as the simultaneous control of multiple markers over time and (2) as the time in target for each marker during the first year of dialysis. Mortality risk was assessed with Cox proportional hazards models.

RESULTS

In the simultaneous control analysis, patients who achieved target for none of the markers had a 51% greater risk for death than those who achieved target for all three markers (reference group). Patients who achieved any target for any single marker had a 35 to 39% higher risk for death, and patients who achieved target for any two of the three markers had a 15 to 21% higher risk for death compared with the reference group. In the time in target analysis, patients with parathyroid hormone in target for 4 quarters had a 25% lower risk for death compared with those who did so for <or=1 quarter (reference group). Patients with calcium in target for 4 quarters had a 14% lower risk, and patients with phosphorus in target for 4 quarters had a 38% lower risk.

CONCLUSIONS

Consistent control of the markers of bone metabolism and disease within published targets is a strong predictor of survival in hemodialysis patients.

摘要

背景与目的

2003年,美国国家肾脏基金会出台了血液透析患者甲状旁腺激素、钙和磷控制指南。

设计、地点、参与者及测量方法:对22937例新进入血液透析的患者进行队列研究,这些患者于2000年7月1日至2002年6月30日期间从一家大型全国性医疗机构中识别出来,并随访至2004年6月30日。持续达标被定义为:(1)多种指标随时间的同时控制;(2)透析第一年中各指标处于目标范围内的时间。使用Cox比例风险模型评估死亡风险。

结果

在同时控制分析中,未达到任何指标目标的患者死亡风险比达到所有三项指标目标的患者(参照组)高51%。达到任何一项单一指标目标的患者死亡风险比参照组高35%至39%,达到三项指标中任意两项指标目标的患者死亡风险比参照组高15%至21%。在达标时间分析中,甲状旁腺激素达标4个季度的患者死亡风险比达标≤1个季度的患者(参照组)低25%。钙达标4个季度的患者死亡风险低14%,磷达标4个季度的患者死亡风险低38%。

结论

在已公布的目标范围内持续控制骨代谢和疾病指标是血液透析患者生存的有力预测指标。

相似文献

引用本文的文献

10
Phosphate Balance and CKD-Mineral Bone Disease.磷平衡与慢性肾脏病-矿物质和骨异常
Kidney Int Rep. 2021 May 17;6(8):2049-2058. doi: 10.1016/j.ekir.2021.05.012. eCollection 2021 Aug.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验